| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Results of Operations and Financial Condition
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 10 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +8 more
Defined terms included below shall have the same meaning as terms defined and included in the Company’s definitive proxy statement/prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 1, 2026 (the “Pro... |
| 09 Nov 2026 |
8-K: Regulation FD Disclosure
Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing |
| 05 Nov 2026 |
8-K: Regulation FD Disclosure
InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation |
| 05 Nov 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders +1 more
This Notice of Articles was issued by the Registrar on: November 4, 2026 01:34 PM Pacific Time |
| 03 Nov 2026 |
8-K: Regulation FD Disclosure
Vancouver, British Columbia--(Newsfile Corp. - November 3, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidat... |
| 18 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events
Vancouver, BC – September 18, 2026 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unme... |
| 22 Jul 2026 |
8-K: Regulation FD Disclosure; Other Events
This AMENDMENT NO. 1 (this “Amendment”) to that certain Securities Purchase Agreement, dated as of May 19, 2026 (the “Agreement”), by and among Mentari Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the Persons l... |
| 10 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
This Amendment No. 1 to Agreement and Plan of Merger and reorganization (this “Amendment”) is made as of July 6, 2026, with respect to that certain Agreement and Plan of Merger and Reorganization (as amended to date, the “Merger Agreemen... |
| 10 Jun 2026 |
8-K: Other Events
Vancouver, BC - June 4, 2026 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") o... |
| 19 May 2026 |
8-K: Entry into a Material Definitive Agreement; Changes in Control of Registrant +2 more
First Certificate of Merger, including certificate of incorporation of the First Step Surviving Corporation attached as Exhibit A thereto, incorporated by reference into this Agreement |
| 19 May 2026 |
8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders +1 more
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UN... |
| 07 May 2026 |
8-K: Regulation FD Disclosure
Vancouver, BC - May 6th, 2026 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet med... |
| 27 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders +1 more
THIS PREFERRED INVESTMENT OPTION AMENDING AGREEMENT (the “Agreement”) is dated April 24, 2026 between: |
| 03 Apr 2026 |
8-K: Other Events
We have acted as counsel to InMed Pharmaceuticals Inc. (the Company), in connection with the issuance and sale through H.C. Wainwright & Co., LLC (the Sales Agent) as the sales agent from time to time by the Company of its common shares ... |
| 30 Mar 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
VANCOUVER, British Columbia - March 27, 2026 - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 ... |
| 23 Mar 2026 |
8-K: Regulation FD Disclosure
InMed Pharmaceuticals Announces Positive Data from Human BrainOrganoid Neuroinflammation Models Supporting the INM-901Alzheimer's Disease Program |
| 09 Mar 2026 |
8-K: Regulation FD Disclosure
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial |
| 06 Mar 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure
The following unaudited pro forma consolidated financial information of InMed Pharmaceuticals Inc. (the “Company”) is derived from its historical consolidated financial statements and should be read in conjunction with the audited financ... |
| 12 Feb 2026 |
8-K: Regulation FD Disclosure
Vancouver, British Columbia - February 11, 2026 - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidat... |
Loading...